A new approach that used CRISPR to engineer adipocytes and implant them in mice models of cancer reduced cancer progression.

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) and rare paediatric disease designation ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

Earnings: Life sciences companies witnessed reduced spending from biotech clients in the past two years, but recent interest ...

MaxCyte, Inc., a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the ...

Broken String Biosciences ("Broken String"), a leader in advancing gene editing safety, today opened its Catalyst Early ...

People living with sickle cell are apprehensive about a revolutionary new one-off treatment that has just been approved for use on the NHS. | ITV News Granada ...